OIA
FLNA

Optimum Investment Advisors’s Filana Therapeutics FLNA Stock Holding History

Optimum Investment Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30
Closed -$1K – 891
2021
Q4 		$1K Buy
+30
New +$1.57K ﹤0.01% 813

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Optimum Investment Advisors's FLNA Position: Q1 2022 in Review

Optimum Investment Advisors sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 30 shares — an estimated $1K sold.

Optimum Investment Advisors first reported a position in FLNA in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

  • Optimum Investment Advisors reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Optimum Investment Advisors sold 30 Filana Therapeutics shares in Q1 2022, an estimated $1K.
  • Optimum Investment Advisors first reported a position in Filana Therapeutics in Q4 2021 and held it in 1 quarter.
  • Optimum Investment Advisors's Filana Therapeutics position peaked at $1K in Q4 2021.
  • 163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Optimum Investment Advisors's 13F filing for Q1 2022, filed 8 Apr 2022.